Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

m 6 A‐Modified SNRPA Controls Alternative Splicing of ERCC1 Exon 8 to Induce Cisplatin Resistance in Lung Adenocarcinoma

18 Nov 2024

Abstract excerpt

Abstract Alternative splicing (AS) generates protein diversity and is exploited by cancer cells to drive tumor progression and resistance to many cancer therapies, including chemotherapy. SNRPA is first identified as a spliceosome‐related gene that potentially modulates resistance to platinum chemotherapy. Both the knockout or the knockdown of SNRPA via CRISPR/Cas9 and shRNA techniques can reverse the resistance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiac Structural Anomalies and Repair
Share to Peptidase Inhibition and Analysis
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39555714
DOI: 10.1002/advs.202404609

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

m 6 A‐Modified SNRPA Controls Alternative Splicing of ERCC1 Exon 8 to Induce Cisplatin Resistance in Lung AdenocarcinomaPMID 39555714Read ↗

The role of alternative splicing in cancer: From oncogenesis to drug resistance.Semantic proximity Read ↗

Genome-scale CRISPR-Cas9 screen identifies PAICS as a therapeutic target for EGFR wild-type NSCLCSemantic proximity Read ↗

Alternative mRNA Splicing and Promising Therapies in Cancer.Semantic proximity Read ↗

mRNA splicing variants: exploiting modularity to outwit cancer therapy.Semantic proximity Read ↗

Regulation of AUF1 alternative splicing by hnRNPA1 and SRSF2 modulate the sensitivity of ovarian cancer cells to cisplatinSemantic proximity Read ↗

U2AF1 mutation connects DNA damage to the alternative splicing of RAD51 in lung adenocarcinomas.Semantic proximity Read ↗

Splicing dysregulation in cancer: from mechanistic understanding to a new class of therapeutic targets.Semantic proximity Read ↗

Elevated PAF1-RAD52 axis confers chemoresistance to human cancersSemantic proximity Read ↗

Inhibition of USP28 overcomes Cisplatin-Resistance of Squamous Tumors by Suppression of the Fanconi Anemia PathwaySemantic proximity Read ↗

Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.Semantic proximity Read ↗

High expression of long non‐coding RNA <i>AFAP1‐AS1</i> predicts chemoradioresistance and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapySemantic proximity Read ↗

LncRNA FAM83H-AS1 Amplification is Associated With a Poor Prognosis in Lung Adenocarcinoma and Can Serve as A Therapeutic TargetSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.